Previous Article | Next Article 
J Virol, July 1998, p. 5728-5734, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Rabbit Cells Expressing Human CD4 and Human CCR5
Are Highly Permissive for Human Immunodeficiency Virus Type 1 Infection
Roberto F.
Speck,1
Michael L.
Penn,1
Jörg
Wimmer,2
Ursula
Esser,1
Bishop F.
Hague,3
Thomas J.
Kindt,3
Robert E.
Atchison,1 and
Mark A.
Goldsmith1,4,*
Gladstone Institute of Virology and
Immunology,1
Department of
Medicine,4 and
Howard Hughes Medical
Institute,2 University of California, San
Francisco, California, and
Laboratory of Immunogenetics,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Rockville, Maryland3
Received 26 January 1998/Accepted 6 April 1998
 |
ABSTRACT |
To evaluate the feasibility of using transgenic rabbits expressing
CCR5 and CD4 as a small-animal model of human immunodeficiency virus
type 1 (HIV) disease, we examined whether the expression of the human
chemokine receptor (CCR5) and human CD4 would render a rabbit cell line
(SIRC) permissive to HIV replication. Histologically, SIRC cells
expressing CD4 and CCR5 formed multinucleated cells (syncytia) upon
exposure to BaL, a macrophagetropic strain of HIV that uses CCR5 for
cell entry. Intracellular viral capsid p24 staining showed abundant
viral gene expression in BaL-infected SIRC cells expressing CD4 and
CCR5. In contrast, neither SIRC cells expressing CD4 alone nor murine
3T3 cells expressing CCR5 and CD4 exhibited significant expression of
p24. These stably transfected rabbit cells were also highly permissive
for the production of virions upon infection by two other
CCR5-dependent strains (JR-CSF and YU-2) but not by a CXCR4-dependent
strain (NL4-3). The functional integrity of these virions was
demonstrated by the successful infection of human peripheral blood
mononuclear cells (PBMC) with viral stocks prepared from these
transfected rabbit cells. Furthermore, primary rabbit PBMC were found
to be permissive for production of infectious virions after
circumventing the cellular entry step. These results suggest that a
transgenic rabbit model for the study of HIV disease may be feasible.
 |
INTRODUCTION |
An important scientific goal has
been the development of small-animal models of human immunodeficiency
virus type 1 (HIV) infection that simulate the stages of HIV disease in
humans (32, 39, 46, 53). Even though severe combined
immunodeficiency (SCID) mice transplanted with fetal human tissue
(e.g., thymus or peripheral blood lymphocytes [reviewed in reference
47]) provide the means to study specific organ
pathology induced by HIV in vivo, they do not fully represent the
complex immunopathogenesis of HIV disease, which involves different
tissues and occurs over an extended period of time, resulting in AIDS
(48). Of the small animals tested as alternative models,
rabbits have been proposed to be the most promising in certain respects
(53). Infection with HIV, defined as the replication of
detectable virus in the host and the development of antibodies to HIV,
has been well documented in native rabbits in vivo (14, 20, 26,
36, 49). However, immunosuppression in HIV-infected rabbits has
been observed inconsistently, and other clinical signs have been
detected in rabbits only upon exposure to both human T-cell leukemia
virus type 1 and HIV (36). The absence of AIDS-like symptoms
in these animals may be explained by the low level of viral
replication. Viral replication has been observed in native rabbit cells
in vitro but never at levels approaching that in human cells (29,
37, 57). The production of mature and infectious viral particles
relies on the accurate interplay of regulatory HIV proteins with
cellular host factors (4, 12, 28, 30, 44, 54, 59). Unlike
those in murine cells (56), cellular host factors in rabbit
cells may support regulatory HIV proteins critical for viral
transcription, suggesting that the main barrier to the replication
cycle occurs before transcription, presumably at the level of viral
entry (8).
Efficient HIV entry has long been recognized to require the human cell
surface protein CD4 (43). However, expression of human CD4
does not render cells in mice and rabbits entirely permissive to the
HIV replication cycle (10, 18, 42). The recent discovery that human chemokine receptors are essential cofactors for HIV entry
into cells might explain the viral entry block in these cells (3,
9, 16, 17, 19). The principal chemokine receptors for HIV entry
are CCR5 (3, 16, 17, 58), which mediates viral entry into
macrophages (macrophagetropic viruses), and CXCR4 (19),
which mediates entry into transformed T-cell lines (T-cell line-tropic
viruses). Macrophagetropic viruses (using CCR5) predominate in
HIV-positive patients over a long period of time (51) and
may be responsible for sexual transmission of HIV (13, 41, 50,
60). In contrast, T-cell line-tropic viruses (using CXCR4) emerge
in at least half of patients later in the course of HIV disease and
have been associated with an acceleration of the immunodeficiency
(11, 27, 33).
These findings suggest the possibility that a small-animal model of HIV
disease could be generated by the expression of human CD4 and
coreceptors in transgenic lines. However, in mice such transgenes were
recently found to be insufficient to support HIV replication, which is
likely to be the result of postentry restrictions (6).
Alternatively, since earlier work suggested that the main restriction
in rabbit cells may be at the level of viral entry, rabbit cells
expressing human chemokine receptors and CD4 might permit robust viral
replication and spread. The present study was performed to evaluate the
feasibility of transgenic rabbits expressing human CCR5 and CD4 as a
small-animal model of HIV infection. Using transfected cell lines, we
compared the permissivity of rabbit-, mouse-, and human-derived cells
for HIV infection after introduction of human CCR5 and CD4.
 |
MATERIALS AND METHODS |
Cells.
HeLa cells expressing human CD4 (HeLa-CD4, provided
by B. Chesebro) (52) or both CD4 and CCR5 (HeLa-CD4/CCR5,
provided by D. Kabat) (52) and 3T3 cells (a murine
fibroblast cell line, provided by D. Littman) (16)
expressing human CD4 (3T3-CD4) or both CD4 and CCR5 (3T3-CD4/CCR5) were
grown as previously described (16, 52). To generate rabbit
cells expressing human CD4, parental SIRC cells (a rabbit
fibroblast-like cell line derived from the cornea of a normal rabbit
with no detectable reverse transcriptase activity; American Type
Culture Collection [ATCC CCL-60], Rockville, Md.) were transfected by
the calcium phosphate method with an expression vector (pcDNA3;
Invitrogen, Carlsbad, Calif.) encoding human CD4 and a neomycin
resistance gene (pCD4neo [25]) and were selected in
culture medium with 400 µg of neomycin (Life Technologies, Grand
Island, N.Y.) per ml. To introduce human CCR5, SIRC-CD4 cells were
transfected with an expression vector (LPXsrf-CCR5; see below) encoding
an epitope-tagged form of human CCR5 (5) and a puromycin
resistance gene and were selected in medium containing 0.5 µg of
puromycin per ml. Clones for surface expression of either CD4 or both
CD4 and CCR5 were screened by flow cytometry (see below). Human
peripheral blood mononuclear cells (PBMC) from random donors and rabbit
PBMC were recovered by Ficoll-Hypaque density gradient centrifugation
(Histopaque 1077; Sigma Diagnostics). Human and rabbit PBMC were
activated overnight by incubation in RPMI 1640 medium (Mediatech) with
phytohemagglutinin (PHA; 5 mg/ml; Sigma) or PHA-M (2 ml of rehydrated
PHA-M per 100 ml of culture medium; Life Technologies), respectively,
per ml overnight. Human macrophages were isolated as previously
described by Miller et al. (45).
Construction of the CCR5 expression plasmid.
Plasmid
pcDNA3-CCR5 (5) was digested with HindIII and
XhoI, which released the epitope-tagged CCR5 fragment. This
fragment was then ligated into the linearized retroviral vector LPXsrf, which had been digested with HindIII and
SalI. LPXsrf (provided by A. DeFranco) is a Moloney murine
leukemia virus-based retroviral vector containing a puromycin
resistance gene.
Flow cytometry.
Fluorescence-activated cell sorting (FACS)
was performed as previously described (5), using a
phycoerythrin-conjugated monoclonal antibody (MAb) against CD4 (Leu-3a;
Becton Dickinson, San Jose, Calif.) and a murine MAb against the
epitope tag of CCR5 (anti-FLAG MAb M1; Eastman Kodak Co., New Haven,
Conn.).
Transfection.
Transfection to assess CD4 downregulation by
Nef was performed with SIRC-CD4 cells. Transfections for assessing
auxiliary HIV gene function were done in SIRC-CD4, HeLa-CD4, and
3T3-CD4 cells in triplicate. All transfections were performed by the
calcium phosphate method (Profection Mammalian Transfection Systems,
Madison, Wis.). Testing was initiated 48 h after transfection as
described below.
To assess viral gene expression independently of viral entry, cells
were transfected with the molecular clone pNL4-3 (see below).
Supernatants of the transfected cells were assessed for viral capsid
p24 antigen production by enzyme-linked immunosorbent assay (ELISA)
(HIV-1 ELISA; Dupont, NEN, Life Science Products, Boston, Mass.).
Further, human PHA-blasted PBMC were exposed to the supernatants to
determine if the virions produced by the various cell lines were mature
and able to initiate infection in indicator cells. Virus production in
these PBMC was verified by assessing p24 viral expression in the
supernatant.
To assess CD4 downregulation by Nef, SIRC-CD4 cells were cotransfected
by pNef (expression vector [
25]) and pCMV4-CD8
(provided
by R. Geleziunas). Because cotransfected plasmids typically
enter
the same cells (
25), CD8
+ cells represent
cells most likely to have been successfully transfected
by pNef.
Transfected cells were stained with phycoerythrin-labeled
MAb against
CD4 and fluorescein isothiocyanate-labeled MAb against
CD8 (Becton
Dickinson) and subsequently analyzed for CD4 expression
by FACS by
gating on CD8
+ cells.
To assess Tat function, pSVtat (Tat expression vector) and pLTR-CAT
(reporter construct encoding chloramphenicol transferase
[CAT]
activity driven by a long terminal repeat [LTR]) (both provided
by M. Peterlin) (
4) and pSV

-gal (Promega, Madison, Wis.) were
cotransfected in equimolar amounts. To assess Rev function, pCMVrev
(Rev expression vector) and pDM128 (reporter construct) (both
provided
by T. Parslow) (
31) and pSV

-gal were cotransfected
in
equal amounts. In both cases, the cotransfection with pSV

-gal
allowed for constitutive expression of

-galactosidase. To compensate
for the different transfection efficiencies of the cell lines,
equivalent amounts of cellular extract as determined by

-galactosidase
activity (Invitrogen) were assayed for CAT activity
with an ELISA
kit (Boehringer Mannheim Co., Indianapolis, Ind.).
To assess whether primary rabbit cells are able to produce mature
virions independently of viral entry, activated rabbit PBMC
(2 × 10
6) were electroporated with 15 µg of pYU-2 DNA (see
below) at 950
µFD and 280 V (Bio-Rad Gene Pulser), and the
supernatant was harvested
2 days after electroporation. To examine
whether virion particles
produced by rabbit PBMC are functional, human
PBMC were exposed
to this supernatant and were monitored over time for
p24 generation.
Viruses.
Viral stocks of YU-2 and NL4-3 were obtained by
transfecting 293T cells with the molecular clones pYU-2 and pNL4-3
(from B. Hahn and M. Martin via the NIH AIDS Research and Reference
Reagent Program) (1, 40). Viral stocks of BaL (from R. Gallo, S. Gartner, and M. Popovic via the NIH AIDS Research and
Reference Reagent Program) (23) were grown on macrophages,
and viral stocks of JR-CSF (provided by B. Chesebro) (35)
were expanded in PHA-activated PBMC from healthy donors. YU-2, BaL, and
JR-CSF are macrophagetropic viruses which predominantly use CCR5 for
viral entry. YU-2, in addition, can enter cells by using CCR3 (3,
9, 16, 52). NL4-3 has a tropism for T cells and uses
predominantly CXCR4 for cell entry (52). High-titer HIV
aliquots with viral capsid p24 values greater than 150 ng/ml were used
for all inoculations.
Histology.
Infected cells were fixed in 2% paraformaldehyde
for 15 min, washed, and dried at room temperature. Cells were
subsequently stained with hematoxylin-eosin and examined by light
microscopy.
Northern blotting.
Northern blot analysis was performed as
described previously (38), using an
-32P-labeled fragment of full-length YU-2.
p24 measurements.
The intracellular p24 assay measuring cell
entry of HIV was performed as previously described (5). For
secreted p24 antigen, 1 day after plating, SIRC, HeLa, and 3T3 cells
expressing CD4 or both CD4 and CCR5 into a 96-well plate
(104 cells/well) were inoculated with HIV strains.
Twenty-four hours after infection, the cells were washed three times to
remove exogenous virus and the medium was replaced. Culture
supernatants were harvested 2 days after infection and analyzed for p24
antigen content.
 |
RESULTS |
Nef, Tat, and Rev functions in rabbit, human, and murine
cells.
To determine whether SIRC cells support the functions of
select regulatory HIV proteins, we studied the activities of Nef, Tat,
and Rev. First, Nef promotes the endocytosis and lysosomal degradation
of cell surface CD4 in human cells (22) through mechanisms
that are incompletely understood (2, 24). This function of
Nef was studied by transfecting SIRC-CD4 cells with expression vectors
encoding Nef and cell surface CD8. Concomitantly supplied plasmids are
typically taken up by the same cells. Thus, after staining with a MAb
against CD8, gating on CD8+ cells selected cells most
likely to be transfected with Nef. CD8+ cells were
subsequently analyzed for CD4 downregulation. CD4 expression was
decreased by approximately 60% in SIRC-CD4 cells transfected with a
Nef-encoding vector, which is similar to the decrease in human-derived
cells (21) (Fig. 1A).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Rabbit cells support Nef, Tat, and Rev function. (A) To
estimate CD4 downregulation by Nef, a vector encoding Nef and a vector
encoding CD8 were cotransfected into SIRC-CD4 cells. Surface protein
expression was detected by staining with a MAb against CD4 or CD8
followed by FACS analysis. Cotransfection was performed because
plasmids typically enter the same cells. By gating on CD8+
cells, mainly cells transfected with pNef were analyzed for CD4
expression. (B) Tat function was measured in cells cotransfected with a
reporter construct (pLTR-CAT) and a vector encoding Tat protein. (C)
Rev function was measured in cells cotransfected with a reporter
construct (pDM128) and a vector encoding Rev protein. All analyses were
performed in triplicate. OD(405), optical density at 405 nm.
|
|
Second, Tat is a potent activator of HIV transcription, and it requires
cellular host factors to be fully active (
28,
30,
44,
59).
To assess this function, rabbit, human, and murine
cells were
cotransfected with a reporter construct (pLTR-CAT),
an expression
vector for Tat (pSVtat), and a constitutive expression
vector for

-galactosidase. The cotransfection with an expression
vector for

-galactosidase allowed us to correct for different
transfection
efficiencies between the cell lines. Rabbit cells
clearly supported Tat
activity detected by CAT induction, although
at somewhat lower levels
than did human cells (Fig.
1B). In contrast,
murine cells did not
support Tat-dependent transactivation of
the LTR substantially over
background levels (Fig.
1B).
Third, Rev controls splicing and the nuclear export of viral RNA
species through interactions with cellular proteins and thus
mediates
the ordered temporal expression of the various gene products
(
12,
54). In the absence of intact Rev function, HIV transcripts
reach
the cytoplasm exclusively in the form of the multiply spliced
2-kb mRNA
species, which encode regulatory HIV proteins, and not
in the form of
unspliced (9-kb) or singly spliced (4-kb) mRNA,
both of which encode
structural HIV proteins. Rev function was
assessed by a reporter
construct (pDM128) and by supplying Rev
by an expression vector
(pCMVrev) (
31). Rev activity was clearly
evident in SIRC
cells, but this activity was somewhat lower than
that in human cells
and much more prominent than that in murine
cells (Fig.
1C). These
findings demonstrate that rabbit cells,
unlike murine cells, bear the
cellular host factors required to
support the functions of HIV proteins
that are critical for the
HIV replication cycle.
SIRC-CD4 cells transfected by pNL4-3 produce infectious
viruses.
To determine if SIRC cells can support production of
mature HIV virions independently of viral entry, SIRC-CD4 cells were transfected with the proviral molecular clone pNL4-3 to circumvent the
cellular entry step. SIRC-CD4 cells clearly supported viral production,
although at levels somewhat lower than that of HeLa-CD4 cells
transfected with pNL4-3 (Fig. 2A). In
contrast, no p24 antigen was detected upon transfection of murine
3T3-CD4 cells (Fig. 2A). Functional integrity of virions produced by
rabbit cells was shown by the production of p24 antigen of human PBMC
exposed to supernatants from transfected rabbit cell cultures (Fig.
2B), while PBMC exposed to supernatant from transfected murine cells
showed no signs of infection. Thus, rabbit cells, unlike murine cells,
are able to carry out the basic postentry activities to produce mature
virions. This finding implies that the major barrier to the HIV
replication cycle in rabbit cells occurs before reverse transcription.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Rabbit cells produce infectious viral particles
independently of viral entry. (A) Cells were transfected by the
molecular clone pNL4-3. Two days later, supernatants were analyzed for
the production of viral capsid p24 antigen. (B) To assess the
functional integrity of virions produced by transfection, human PBMC
were exposed to the supernatants of transfected cells, and p24 levels
in supernatants of the PBMC were analyzed at different time points.
|
|
SIRC cells expressing human CD4 and CCR5 form multinucleated giant
cells upon exposure to CCR5-dependent viral strains.
To examine
directly the effects of chemokine receptor and CD4 expression in rabbit
cells on the HIV replication cycle, we generated SIRC cell lines that
stably expressed CCR5 and CD4. Cell surface expression of these
proteins was verified by flow cytometry (data not shown).
The induction of multinucleated giant cells (syncytia) has been
considered a key feature of T-cell line-tropic viruses (
7,
15,
33,
34,
51). However, we and others have recently
suggested that the
ability to induce syncytia experimentally rather
reflects the type of
coreceptor expressed in given target cells
infected by distinct viruses
(
3,
9,
16,
17,
52). Indeed,
in SIRC-CD4/CCR5 cultures
infected by the CCR5-dependent HIV strain
BaL, multinucleated giant
cells were abundant, indicating the
ability of macrophagetropic viruses
to induce such cytopathic
effects in the context of expression of the
proper coreceptors
(Fig.
3). In contrast,
no cytopathic effects were seen in rabbit
cells expressing only CD4
after infection with either CCR5-dependent
viral strain or in
SIRC-CD4/CCR5 cells infected by NL4-3, which
uses CXCR4 (not shown).
Similar disruptions of cellular morphology
were also observed in
SIRC-CD4/CCR5 cell cultures infected by
YU-2 and JR-CSF, both of which
are capable of using CCR5 (not
shown). These findings demonstrate that
the main barrier to HIV
infection in rabbit cells is at the level of
viral entry and suggest
that rabbit cells expressing CD4 and CCR5 may
be highly susceptible
to the HIV replication cycle.

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 3.
CCR5-dependent induction of syncytia in SIRC-CD4/CCR5
cells infected by BaL. Hematoxylin-eosin staining was performed 2 days
after infection.
|
|
Viral gene expression in SIRC-CD4/CCR5 cells infected by YU-2.
To assess the ability of rabbit cells to support viral gene expression
upon infection by HIV, we measured viral transcripts in the cytoplasm
of infected cells by Northern blot analysis. SIRC-CD4/CCR5 cells
infected with YU-2 displayed the expected 2-, 4-, and 9-kb classes of
viral mRNA, indicating intact viral promoter, transactivation, and
splicing functions (Fig. 4). No viral
transcripts were detected in cells expressing only CD4 that were
exposed to HIV. The intensity of the hybridization signals was similar
with RNAs obtained from infected rabbit or human cells expressing CD4
and CCR5 (Fig. 4).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 4.
HIV-specific hybridization transcripts obtained from
total RNA of infected rabbit and human cell cultures. Two days after
infection with YU-2, total RNA was isolated, resolved by
electrophoresis, and transferred onto a Zeta GT probe. The blot was
probed with an -32P-labeled fragment of full-length
YU-2. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
|
|
To assess viral protein production in rabbit cells, SIRC cells
expressing CD4 or both CD4 and CCR5 were exposed to BaL. Two
days
later, the cells were fixed, permeabilized, and stained for
intracellular viral capsid p24 expression. SIRC-CD4/CCR5 cells
showed
significant expression of intracellular p24 after infection
with BaL.
In contrast, neither SIRC-CD4 cells nor murine 3T3-CD4/CCR5
cells
exhibited significant expression of p24 upon inoculation
with BaL (Fig.
5).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
Intracellular viral gene expression indicates vigorous
viral replication. After fixation and permeabilization, SIRC cells
infected with BaL were stained with MAb against intracellular p24
(p24i) antigen.
|
|
Production of mature virions by SIRC-CD4/CCR5 cells upon exposure
to various CCR5-dependent viral strains.
To assess the
permissiveness of rabbit cells expressing CD4 and CCR5 to various
CCR5-dependent viral strains, we also assessed viral capsid p24
production in the supernatant of infected cell cultures. SIRC-CD4/CCR5
cells and HeLa-CD4/CCR5 cells showed abundant secretion of p24 upon
infection with BaL, YU-2, and JR-CSF, all of which are viral strains
that use CCR5 as a coreceptor (Fig. 6A).
The amounts of p24 antigen produced were similar in rabbit and human
cells but varied depending on the viral strain used for inoculation. No
infection of rabbit cells by NL4-3 was observed (Fig. 6A), which is
consistent with the lack of human CXCR4 on these cells. No p24 antigen
was produced by murine cells infected by these viruses, even in the
presence of human CD4 and CCR5. These results indicate that the
expression of CCR5 and CD4 on SIRC cells confers general susceptibility
to infection with CCR5-dependent HIV strains but not with
CXCR4-dependent strains.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Extracellular viral gene expression and production of
mature virions in rabbit cells. (A) Two days after infection of cells
with various HIV strains, culture supernatants were harvested and
analyzed for p24 antigen. (B) To test the functional integrity of
virions produced, human PBMC were exposed to the supernatant of
transfected cells, and p24 levels in supernatants of the PBMC were
analyzed at different time points.
|
|
To determine if the virus produced by rabbit cells was fully
infectious, we inoculated PHA-activated human PBMC with viral
stocks
prepared from infected cell cultures. Viral stocks from
both human and
rabbit cells could be easily propagated in cultured
human PBMC and
reached similar peak values approximately 8 days
after inoculation
although with somewhat different kinetics, indicating
the functional
integrity of virus generated upon infection of
rabbit cells (Fig.
6B).
Primary rabbit PBMC electroporated with pYU-2 produce infectious
virus.
To examine whether primary rabbit PBMC are able to produce
infectious virus upon bypassing the entry step, activated rabbit PBMC
were electroporated with pYU-2. Supernatants of three of six
electroporations showed detectable p24 antigen production with a yield
of 0.05 to 1.5 ng/ml, consistent with a very low transfection
efficiency of primary rabbit PBMC. To assess whether virion particles
produced by rabbit PBMC are functional, human PBMC were exposed to
these supernatants. Indeed, these cultures produced abundant p24
antigen over time (Fig. 7), indicating
that rabbit PBMC are able to support postintegration steps in the HIV replication cycle, leading to release of infectious virions.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 7.
Production of mature virions by primary rabbit PBMC.
Human PBMC were exposed to supernatant of rabbit PBMC, which had been
electroporated with pYU-2 2 days before. As demonstrated by the
abundant production of p24 antigen in human PBMC, virions generated by
rabbit PBMC were infectious.
|
|
 |
DISCUSSION |
This study provides a clear demonstration that expression of human
CCR5 in rabbit cells abolishes the entry block for HIV and permits HIV
replication at levels similar to those in human cells. In addition, the
virions produced by HIV-infected SIRC-CD4/CCR5 cells are intact and
infectious as determined by several criteria. These findings imply that
a transgenic rabbit model for CCR5 and CD4 may be feasible, although it
is impossible to predict the levels of viral replication that would be
achieved in vivo or the extent of disease that would be associated with
such an infection.
The rabbit cell line that we used has no inherent susceptibility to
infection by HIV. Nonetheless, this rabbit cell line appeared to have
the necessary host-specific factors to support the regulatory HIV
proteins that are critical for infectivity. First, Nef downregulated CD4 in SIRC-CD4 cells to an extent similar to that reported for human
and murine cells (21), consistent with the notion that Nef-mediated downregulation of CD4 is neither species nor tissue specific (21). Second, the HIV LTR in SIRC cells was clearly transactivated by Tat, although somewhat less efficiently than in HeLa
cells. Other reports have suggested that Tat function is intact in
native rabbit T cells (8), implying that at least certain
rabbit tissues express the cellular host factors needed for Tat
function. Third, the expression of early and late viral gene products
requires host cell factors to interact appropriately with Rev and its
responsive elements in viral RNA (12, 54). The present
transfection data indicated that Rev constructs functioned properly in
rabbit cells, albeit somewhat less efficiently than in HeLa cells.
Insignificant levels of Tat and Rev function were seen in murine cells
in these experiments, as previously reported (56). Thus, our
findings confirm and extend the observations of intact function of Tat
and Rev previously reported in other rabbit cell lines (8)
and, in addition, demonstrate intact Nef function in rabbit cells.
Evaluating the activity of HIV proteins is useful for delineating
potential barriers to HIV replication in a cell line, but it provides
no information about the ability of the cells to produce infectious
viral particles. To test the ability of rabbit cells to support the HIV
replication cycle independently of viral entry, we transfected the
cells with the molecular clone pNL4-3. Indeed, consistent with earlier
studies, they produced viral capsid p24 antigen at a lower level than
did HeLa cells (8). The difference in p24 antigen production
may reflect lower transfection efficiency in rabbit cells than in HeLa
cells or lower efficiency of HIV regulatory proteins. Importantly, the
virions produced by this method were infectious, as demonstrated by the
positive infection of human PBMC by viral stocks prepared from these
transfected cells. No viral capsid p24 was detected upon transfection
of murine cells, and as expected, human PBMC exposed to supernatant
from those cells were not infected.
The key experiments in our study were to determine if coexpression of
CD4 and CCR5 would render rabbit cells permissive to HIV infection,
including viral entry and production of virions capable of spreading
infection. Indeed, SIRC-CD4/CCR5 cells infected with BaL, a
macrophagetropic virus, formed massive multinucleated giant cells
(syncytia) and showed complete disruption of the cellular structure, as
was observed in infected HeLa-CD4/CCR5 cells. Similar destruction of
the cell architecture was also observed after infections by the
CCR5-dependent strains, JR-CSF and YU-2, but not after infection with
the CXCR4-dependent strain, NL4-3. No cytopathic effects were observed
in SIRC-CD4 cells infected with BaL. Thus, these results demonstrate
that the main barrier to efficient HIV replication in rabbit cells is
at the level of viral entry and is removed by the expression of human
cell surface molecules. Our observations also substantiate the notion
(3, 9, 16, 17, 52) that syncytium formation is induced not
only by T-cell line-tropic HIV strains but also by macrophagetropic
strains in the context of appropriate cognate coreceptors.
Northern analysis of SIRC-CD4/CCR5 and HeLa-CD4/CCR5 cells infected by
YU-2 showed similar intensities of viral transcripts, which implies
that similar amounts of viral transcripts were produced in these cells.
In contrast to our findings, transcripts from HIV-infected native
rabbit T cells were reported to be of much lower intensity than those
from infected human T cells (8). We believe this difference
reflects inefficient viral entry into native rabbit T cells rather than
a lack of cellular factors supporting Rev function, although
tissue-specific differences in host cell factors cannot be excluded as
a factor in these studies.
Staining for intracellular viral capsid p24 antigen of BaL-infected
SIRC-CD4/CCR5 cells also confirmed vigorous viral gene expression,
which indicates permissivity to the HIV replication cycle and
corroborates the histological findings. In contrast, neither SIRC-CD4
cells nor murine 3T3-CD4/CCR5 cells exhibited significant p24
expression.
The general susceptibility of SIRC CD4/CCR5 cells to CCR5-dependent
strains was also verified by measuring p24 antigen production by cells
infected by JR-CSF, YU-2, and BaL. As expected, no infection could be
documented in SIRC-CD4/CCR5 cells infected with NL4-3, a T-cell
line-tropic virus that uses CXCR4, indicating the selective susceptibility of these cells to CCR5-dependent strains. Since levels
of virus production as assessed by p24 antigen levels were similar in
rabbit and human cells, the lower efficiency of regulatory HIV protein
function in rabbit cells does not appear to be critical for overall
infectivity. The production of viral capsid p24 antigen in
SIRC-CD4/CCR5 cells was 100 to 4,000 times higher (depending on the
viral stain) than that in transformed rabbit T-cell lines lacking
appropriate human chemokine receptors (8).
The final and most crucial test of virion integrity is the ability of
virions to infect other cells. This was demonstrated by their
successful passage to human PBMC. Thus, there are no absolute blocks or
restrictions to the HIV replication cycle and the spread of infectious
HIV virions in rabbit cells. One report has described the production of
immature virions by primary rabbit PBMC infected by HIV
(55). It is more likely that virions infecting primary
rabbit PBMC lacking human chemokine receptors and human CD4 will be
targeted to an unusual endocytic pathway, resulting in their
disruption. Indeed, in the present study, electroporation experiments
using primary rabbit PBMC confirmed that these cells are able to
support postintegration steps in the HIV replication cycle. Thus, we
have no reason to conclude that rabbit PBMC have an intrinsic inability
to carry out the basic activities required for HIV replication.
In conclusion, viral replication in rabbit cells expressing human CCR5
and CD4 in vitro approaches the level seen in human cells and is
markedly higher than that in murine cells. HIV virions produced by
these cells are able to support spreading infection and successfully
infect human PBMC. These findings suggest that transgenic rabbits
expressing CCR5 and CD4 may support reasonable levels of HIV
replication in vivo, and we speculate that such animals might serve as
a useful small-animal model for HIV disease. A small-animal model that
simulates selected stages of HIV transmission and/or disease
pathogenesis in humans would be invaluable for the study of HIV
disease, mechanisms of transmission and pathogenesis, and treatment or
prevention strategies.
 |
ACKNOWLEDGMENTS |
We thank Bruce Chesebro, Anthony DeFranco, Romas Geleziunas,
David Kabat, Dan Littman, Matija Peterlin, and Tris Parslow for materials, Stephen Ordway and Gary Howard for editorial assistance, John Carroll and Stephen Gonzales for the preparation of figures, Yang
He for technical assistance, and Jessica Diamond and Airion Rapaport
for preparing the manuscript.
This work was supported by the J. David Gladstone Institutes, the UCSF
Center for AIDS Research, the UCSF AIDS Clinical Research Center, and
the National Institutes of Health (grants AI28240-09S1 and AI42654-01).
R.F.S. was supported by the Swiss National Science Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Gladstone
Institute of Virology and Immunology, P.O. Box 419100, San Francisco,
CA 94141-9100. Phone: (415) 695-3749. Fax: (415) 826-1514. E-mail: Mark_Goldsmith{at}quickmail.ucsf.edu.
 |
REFERENCES |
| 1.
|
Adachi, A.,
H. E. Gendelman,
S. Koenig,
T. Folks,
R. Willey,
A. Rabson, and M. A. Martin.
1986.
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
J. Virol.
59:284-291[Abstract/Free Full Text].
|
| 2.
|
Aiken, C.,
J. Konner,
N. R. Landau,
M. E. Lenburg, and D. Trono.
1994.
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
Cell
76:853-864[Medline].
|
| 3.
|
Alkhatib, G.,
C. Combadiere,
C. C. Broder,
Y. Feng,
P. E. Kennedy,
P. M. Murphy, and E. A. Berger.
1996.
CC CKR5: A RANTES, MIP-1 , MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science
272:1955-1958[Abstract].
|
| 4.
|
Alonso, A.,
D. Derse, and B. M. Peterlin.
1992.
Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.
J. Virol.
66:4617-4621[Abstract/Free Full Text].
|
| 5.
|
Atchison, R. E.,
J. Gosling,
F. S. Monteclaro,
C. Franci,
L. Digilio,
I. F. Charo, and M. A. Goldsmith.
1996.
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.
Science
274:1924-1926[Abstract/Free Full Text].
|
| 6.
|
Browning, J.,
J. W. Horner,
M. Pettoello-Mantovani,
C. Raker,
S. Yurasov,
R. A. Depinho, and H. Goldstein.
1997.
Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection.
Proc. Natl. Acad. Sci. USA
94:14637-14641[Abstract/Free Full Text].
|
| 7.
|
Chesebro, B.,
K. Wehrly,
J. Nishio, and S. Perryman.
1996.
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes.
J. Virol.
70:9055-9059[Abstract].
|
| 8.
|
Cho, S.,
T. J. Kindt,
T. M. Zhao,
S. Sawasdikosol, and B. F. Hague.
1995.
Replication of HIV type 1 in rabbit cell lines is not limited by deficiencies in tat, rev, or long terminal repeat function.
AIDS Res. Hum. Retroviruses
11:1487-1493[Medline].
|
| 9.
|
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P. D. Ponath,
L. Wu,
C. R. Mackay,
G. LaRosa,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1996.
The b-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell
85:1135-1148[Medline].
|
| 10.
|
Clapham, P.,
A. McKnight,
G. Simmons, and R. Weiss.
1993.
Is CD4 sufficient for HIV entry? Cell surface molecules involved in HIV infection.
Philos. Trans. R. Soc. Lond. Ser. B
342:67-73[Medline].
|
| 11.
|
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 12.
|
Cullen, B. R., and M. H. Malim.
1991.
The HIV-1 rev protein: prototype of a novel class of eukaryotic post-transcriptional regulators.
Trends Biomed. Sci.
16:346-350.
|
| 13.
|
Dean, M.,
M. Carrington,
C. Winkler,
G. A. Huttley,
M. W. Smith,
R. Allikemts,
J. J. Goedert,
S. P. Buchbinder,
E. Vittinghoff,
E. Gomperts,
S. Donfield,
D. Vlahov,
R. Kaslow,
A. Saah,
C. Rinaldo,
R. Detels,
Hemophilia Growth and Development Study,
Multicenter AIDS Cohort Study,
Multicenter Hemophilia Cohort Study,
San Francisco Cohort Study,
ALIVE Study, and S. O'Brien.
1996.
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene.
Science
273:1856-1862[Abstract/Free Full Text].
|
| 14.
|
Debiaggi, M.,
R. Bruno,
M. Carlevari,
G. Achilli,
B. Emanuelli,
P. M. Cereda,
E. Romero, and G. Filice.
1995.
HIV type 1 intraperitoneal infection of rabbits permits early detection of serum antibodies to Gag, Pol, and Env proteins, neutralizing antibodies, and proviral DNA from peripheral blood mononuclear cells.
AIDS Res. Hum. Retroviruses
11:287-296[Medline].
|
| 15.
|
De Jong, J.-J.,
J. Goudsmith,
W. Keulen,
B. Klaver,
W. Krone,
M. Tersmette, and A. De Ronde.
1992.
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.
J. Virol.
66:757-765[Abstract/Free Full Text].
|
| 16.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 17.
|
Dragic, T.,
V. Litwin,
G. P. Allaway,
S. R. Martin,
Y. Huang,
K. A. Nagashima,
C. Cayanan,
P. J. Maddon,
R. A. Koup,
J. P. Moore, and W. A. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature
381:667-673[Medline].
|
| 18.
|
Dunn, C. S.,
M. Mehtali,
L. M. Houdebine,
J. P. Gut,
A. Kirn, and A. M. Aubertin.
1995.
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits.
J. Gen. Virol.
76:1327-1336[Abstract/Free Full Text].
|
| 19.
|
Feng, Y.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 20.
|
Filice, G.,
P. M. Cereda, and O. E. Varnier.
1988.
Infection of rabbits with human immunodeficiency virus.
Nature
335:366-369[Medline].
|
| 21.
|
Garcia, J. V.,
J. Alfano, and A. D. Miller.
1993.
The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4.
J. Virol.
67:1511-1516[Abstract/Free Full Text].
|
| 22.
|
Garcia, J. V., and A. D. Miller.
1991.
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.
Nature
350:508[Medline].
|
| 23.
|
Gartner, S.,
P. Markovits,
D. M. Markovits,
M. H. Kaplan,
R. C. Gallo, and M. Popovic.
1986.
The role of mononuclear phagocytes in HTLV-III/LAV infection.
Science
233:215-219[Abstract/Free Full Text].
|
| 24.
|
Geleziunas, R.,
M. D. Miller, and W. C. Greene.
1996.
Unraveling the function of HIV Type 1 Nef.
AIDS Res. Hum. Retroviruses
12:1579-1582[Medline].
|
| 25.
|
Goldsmith, M. A.,
M. T. Warmerdam,
R. E. Atchison,
M. D. Miller, and W. C. Greene.
1995.
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1. Nef.
J. Virol.
69:4112-4121[Abstract].
|
| 26.
|
Gordon, M. R.,
M. E. Truckenmiller,
D. P. Recker,
D. R. Dickerson,
E. Kuta,
H. Kulaga, and T. J. Kindt.
1990.
Evidence for HIV-1 infection in rabbits.
Ann. N. Y. Acad. Sci.
616:270-280[Medline].
|
| 27.
|
Goudsmit, J.
1995.
The role of viral diversity in HIV pathogenesis.
J. Acquired Immune Defic. Syndr. Hum. Retrovirol.
10:S15-S19.
|
| 28.
|
Greenberg, M. E.,
D. A. Ostapenko, and M. B. Mathews.
1997.
Potentiation of human immunodeficiency virus type 1 Tat by human cellular proteins.
J. Virol.
71:7140-7144[Abstract].
|
| 29.
|
Hague, B. F.,
S. Sawasdikosol,
T. J. Brown,
K. Lee,
D. P. Recker, and T. J. Kindt.
1992.
CD4 and its role in infection of rabbit cell lines by human immunodeficiency virus type 1.
Immunology
89:7963-7967.
|
| 30.
|
Hart, C. E.,
C. Y. Ou,
J. C. Galphin,
J. Moore,
L. T. Bacheler,
J. Wasmuth,
S. R. Petteway, and G. Schochetman.
1989.
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells.
Science
246:488-491[Abstract/Free Full Text].
|
| 31.
|
Hope, T. J.,
X. Huang,
D. McDonald, and T. G. Parslow.
1990.
Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif.
Proc. Natl. Acad. Sci. USA
87:7787-7791[Abstract/Free Full Text].
|
| 32.
|
Klotman, P. E.,
J. Rappaport,
P. Ray,
J. B. Kopp,
R. Franks,
L. A. Bruggeman, and A. L. Notkins.
1995.
Transgenic models of HIV-1.
AIDS
9:313-324[Medline].
|
| 33.
|
Koot, M.,
I. P. M. Keet,
A. H. V. Vos,
R. E. Y. de Goede,
M. T. L. Roos,
R. A. Coutinho,
F. Miedema,
P. T. A. Schellekens, and M. Tersmette.
1993.
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.
Ann. Intern. Med.
118:681-688[Abstract/Free Full Text].
|
| 34.
|
Koot, M.,
A. H. V. Vos,
R. P. M. Keet,
R. E. Y. de Goede,
M. W. Dercksen,
F. G. Terpstra,
R. A. Coutinho,
F. Miedema, and M. Tersmette.
1992.
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.
AIDS
6:49-54[Medline].
|
| 35.
|
Koyanagi, Y.,
S. Miles,
R. T. Mitsuyasu,
J. E. Merrill,
H. V. Vinters, and I. S. Y. Chen.
1987.
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.
Science
236:819-822[Abstract/Free Full Text].
|
| 36.
|
Kulaga, H.,
T. Folks,
R. Rutledge,
M. E. Truckenmiller,
E. Gugel, and T. J. Kindt.
1989.
Infection of rabbits with human immunodeficiency virus 1.
J. Exp. Med.
169:321-326[Abstract/Free Full Text].
|
| 37.
|
Kulaga, H.,
T. M. Folks,
R. Rutledge, and T. J. Kindt.
1988.
Infection of rabbit T-cell and macrophage lines with human immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
85:4455-4459[Abstract/Free Full Text].
|
| 38.
|
Lamson, G., and M. E. Koshland.
1984.
Changes in J chain and µ chain RNA expression as a function of B cell differentiation.
J. Exp. Med.
160:877-892[Abstract/Free Full Text].
|
| 39.
|
Lewis, A. D., and P. R. Johnson.
1995.
Developing animal models for AIDS research progress and problems.
Trends Biotechnol.
13:142-150[Medline].
|
| 40.
|
Li, Y.,
J. C. Kappes,
J. A. Conway,
R. W. Price,
G. M. Shaw, and B. H. Hahn.
1991.
Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes.
J. Virol.
65:3973-3985[Abstract/Free Full Text].
|
| 41.
|
Liu, R.,
W. A. Paxton,
S. Choe,
D. Ceradini,
S. R. Martin,
R. Horuk,
M. E. McDonald,
H. Stuhlmann,
R. A. Koup, and N. R. Landau.
1996.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
Cell
86:367-377[Medline].
|
| 42.
|
Lores, P.,
V. Boucher,
C. Mackay,
M. Pla,
H. von Boehmer,
J. Jami,
F. Barre-Sinoussi, and J.-C. Weill.
1992.
Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection.
AIDS Res. Hum. Retroviruses
8:2063-2071[Medline].
|
| 43.
|
Maddon, P. J.,
A. G. Dalgleish,
J. S. McDougal,
P. R. Clapham,
R. A. Weiss, and R. Axel.
1986.
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
Cell
47:333-348[Medline].
|
| 44.
|
Madore, S. J., and B. R. Cullen.
1993.
Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.
J. Virol.
67:3703-3711[Abstract/Free Full Text].
|
| 45.
|
Miller, M. D.,
M. T. Warmerdam,
I. Gaston,
W. C. Greene, and M. B. Feinberg.
1994.
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
J. Exp. Med.
179:101-113[Abstract/Free Full Text].
|
| 46.
|
Morrow, W. J. W.,
M. Wharton,
D. Lau, and J. A. Levy.
1987.
Small animals are not susceptible to human immunodeficiency virus infection.
J. Gen. Virol.
68:2253-2257[Abstract/Free Full Text].
|
| 47.
|
Mosier, D. E.
1996.
Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice.
Adv. Immunol.
63:79-125[Medline].
|
| 48.
|
Pantaleo, G.,
C. Graziosi, and A. S. Fauci.
1993.
The immunopathogenesis of human immunodeficiency virus infection.
N. Engl. J. Med.
328:327-335[Free Full Text].
|
| 49.
|
Reina, S.,
P. Markham,
E. Gard,
F. Rayed,
M. Reitz,
R. C. Gallo, and O. E. Varnier.
1993.
Serological, biological, and molecular characterization of New Zealand White rabbits infected by intraperitoneal inoculation with cell-free human immunodeficiency virus.
J. Virol.
67:5367-5374[Abstract/Free Full Text].
|
| 50.
|
Samson, M.,
F. Libert,
B. J. Doranz,
J. Rucker,
C. Liesnard,
C.-M. Farber,
S. Saragosti,
C. Lapoumeroulie,
J. Cognaux,
C. Forceille,
G. Muyldermans,
C. Verhofstede,
G. Burtonboy,
M. Georges,
T. Imai,
S. Rana,
Y. Yi,
R. J. Smyth,
R. G. Collman,
R. W. Doms,
G. Vassart, and M. Parmentier.
1996.
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
Nature
382:722-725[Medline].
|
| 51.
|
Schuitemaker, H.,
M. Koot,
N. A. Kootstra,
M. W. Dercksen,
R. E. Y. De Goede,
R. P. van Steenwijk,
J. M. A. Lange,
J. Schattenkerk,
F. Miedema, and M. Tersmette.
1992.
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations.
J. Virol.
66:1354-1360[Abstract/Free Full Text].
|
| 52.
|
Speck, R. F.,
B. Chesebro,
R. E. Atchison,
K. Wehrly,
I. F. Charo, and M. A. Goldsmith.
1997.
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.
J. Virol.
71:7136-7139[Abstract].
|
| 53.
|
Spertzel, R. O., and Public Health Service Animal Models Committee.
1989.
Animal models of human immunodeficiency virus infection.
Antiviral Res.
12:223-230[Medline].
|
| 54.
|
Trono, D., and D. Baltimore.
1990.
A human cell factor is essential for HIV-1 Rev action.
EMBO J.
9:4155-4160[Medline].
|
| 55.
|
Tseng, C. K.,
J. Leibowitz, and S. Sell.
1994.
Defective infection of rabbit peripheral blood monocyte cultures with human immunodeficiency virus type 1.
AIDS Res. Hum. Retroviruses
10:285-293[Medline].
|
| 56.
|
Winslow, B. J., and D. Trono.
1993.
The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent.
J. Virol.
67:2349-2354[Abstract/Free Full Text].
|
| 57.
|
Yamamura, Y.,
M. Kotani,
M. I. H. Chowdhury,
N. Yamamoto,
K. Yamaguchi,
H. Karasuyama,
Y. Katsura, and M. Miyasaka.
1991.
Infection of human CD4+ rabbit cells with HIV-1: the possibility of the rabbit as a model for HIV-1 infection.
Int. Immunol.
3:1183-1187[Abstract/Free Full Text].
|
| 58.
|
Zhang, L.,
C. D. Carruthers,
T. He,
Y. Huang,
Y. Cao,
G. Wang,
B. Hahn, and D. D. Ho.
1997.
HIV Type 1 subtypes, coreceptor usage, and CCR5 polymorphism.
AIDS Res. Hum. Retroviruses
13:1357-1366[Medline].
|
| 59.
|
Zhou, Q., and P. A. Sharp.
1995.
Novel mechanism and factor for regulation by HIV-1 Tat.
EMBO J.
14:321-328[Medline].
|
| 60.
|
Zhu, T.,
H. Mo,
N. Wang,
D. S. Nam,
Y. Cao,
R. A. Koup, and D. D. Ho.
1993.
Genotypic and phenotypic characterization of HIV-1 in patients with primary infection.
Science
261:1179-1181.
|
J Virol, July 1998, p. 5728-5734, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ikeda, T., Ohsugi, T., Kimura, T., Matsushita, S., Maeda, Y., Harada, S., Koito, A.
(2008). The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res
36: 6859-6871
[Abstract]
[Full Text]
-
Schaller, T., Hue, S., Towers, G. J.
(2007). An Active TRIM5 Protein in Rabbits Indicates a Common Antiviral Ancestor for Mammalian TRIM5 Proteins. J. Virol.
81: 11713-11721
[Abstract]
[Full Text]
-
Hu, J., Peng, X., Schell, T. D., Budgeon, L. R., Cladel, N. M., Christensen, N. D.
(2006). An HLA-A2.1-Transgenic Rabbit Model to Study Immunity to Papillomavirus Infection. J. Immunol.
177: 8037-8045
[Abstract]
[Full Text]
-
Keppler, O. T., Allespach, I., Schuller, L., Fenard, D., Greene, W. C., Fackler, O. T.
(2005). Rodent Cells Support Key Functions of the Human Immunodeficiency Virus Type 1 Pathogenicity Factor Nef. J. Virol.
79: 1655-1665
[Abstract]
[Full Text]
-
Koito, A., Kameyama, Y., Cheng-Mayer, C., Matsushita, S.
(2003). Susceptibility of Mink (Mustera vision)-Derived Cells to Replication by Human Immunodeficiency Virus Type 1. J. Virol.
77: 5109-5117
[Abstract]
[Full Text]
-
LaBonte, J. A., Babcock, G. J., Patel, T., Sodroski, J.
(2002). Blockade of HIV-1 Infection of New World Monkey Cells Occurs Primarily at the Stage of Virus Entry. JEM
196: 431-445
[Abstract]
[Full Text]
-
Crotty, S., Hix, L., Sigal, L. J., Andino, R.
(2002). Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J. Gen. Virol.
83: 1707-1720
[Abstract]
[Full Text]
-
Keppler, O. T., Yonemoto, W., Welte, F. J., Patton, K. S., Iacovides, D., Atchison, R. E., Ngo, T., Hirschberg, D. L., Speck, R. F., Goldsmith, M. A.
(2001). Susceptibility of Rat-Derived Cells to Replication by Human Immunodeficiency Virus Type 1. J. Virol.
75: 8063-8073
[Abstract]
[Full Text]
-
Mariani, R., Rasala, B. A., Rutter, G., Wiegers, K., Brandt, S. M., Kräusslich, H.-G., Landau, N. R.
(2001). Mouse-Human Heterokaryons Support Efficient Human Immunodeficiency Virus Type 1 Assembly. J. Virol.
75: 3141-3151
[Abstract]
[Full Text]
-
Mariani, R., Rutter, G., Harris, M. E., Hope, T. J., Kräusslich, H.-G., Landau, N. R.
(2000). A Block to Human Immunodeficiency Virus Type 1 Assembly in Murine Cells. J. Virol.
74: 3859-3870
[Abstract]
[Full Text]
-
Chan, S. Y., Speck, R. F., Power, C., Gaffen, S. L., Chesebro, B., Goldsmith, M. A.
(1999). V3 Recombinants Indicate a Central Role for CCR5 as a Coreceptor in Tissue Infection by Human Immunodeficiency Virus Type 1. J. Virol.
73: 2350-2358
[Abstract]
[Full Text]
-
Langley, R. J., Prince, G. A., Ginsberg, H. S.
(1998). HIV type-1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus). Proc. Natl. Acad. Sci. USA
95: 14355-14360
[Abstract]
[Full Text]